Norges Bank Makes New $293.42 Million Investment in United Therapeutics Corporation $UTHR

Norges Bank acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 602,191 shares of the biotechnology company’s stock, valued at approximately $293,418,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Clearstead Advisors LLC increased its holdings in United Therapeutics by 8.9% during the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 23 shares in the last quarter. Independent Advisor Alliance increased its holdings in United Therapeutics by 3.3% during the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after purchasing an additional 27 shares in the last quarter. Bessemer Group Inc. increased its holdings in United Therapeutics by 2.6% during the 3rd quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock worth $472,000 after purchasing an additional 28 shares in the last quarter. Signaturefd LLC increased its holdings in United Therapeutics by 4.1% during the 4th quarter. Signaturefd LLC now owns 896 shares of the biotechnology company’s stock worth $437,000 after purchasing an additional 35 shares in the last quarter. Finally, WealthCollab LLC increased its holdings in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total value of $5,274,800.00. Following the transaction, the chief financial officer owned 18,876 shares in the company, valued at approximately $9,956,712.48. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 614,043 shares of company stock valued at $344,991,997 in the last quarter. 8.60% of the stock is currently owned by corporate insiders.

United Therapeutics Stock Down 0.8%

UTHR stock opened at $540.05 on Wednesday. The firm has a market cap of $22.93 billion, a PE ratio of 19.94, a P/E/G ratio of 1.77 and a beta of 0.57. The business has a 50 day moving average of $566.86 and a 200-day moving average of $516.87. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter in the previous year, the company posted $6.63 EPS. United Therapeutics’s revenue for the quarter was down 1.6% on a year-over-year basis. On average, research analysts expect that United Therapeutics Corporation will post 26.92 earnings per share for the current year.

Analyst Ratings Changes

UTHR has been the subject of a number of recent research reports. Cantor Fitzgerald boosted their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Bank of America upped their target price on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. Morgan Stanley set a $516.00 target price on United Therapeutics in a report on Thursday, May 7th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, UBS Group upped their target price on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.